CB Insights Unveils Industry's First AI Agent Workforce for M&A, Partnerships, Competitive Intelligence, Deal Sourcing, GTM, and More
26.6.2025 18:49:00 CEST | Business Wire | Press Release
CB Insights, the leading provider of predictive market intelligence, today announced the launch of its Team of Agents – the industry's first comprehensive AI agent workforce designed specifically to enable business leaders with always-on market intelligence for strategic decision-making. CB Insights’ growing team of agents starts with 11 specialized agents that work continuously to uncover insights, translate proprietary data into action, and accelerate smart decisions by providing the external intelligence layer that enterprises need to compete effectively across business development, investments, partnerships, GTM, and competitive intelligence.
While generic AI assistants struggle with business context and lack reliable external data, CB Insights' Team of Agents delivers validated intelligence and data science on over 10 million companies and 1,500 tech markets through purpose-built specialists that understand the nuanced requirements of strategic business functions.
Enterprise clients are already hiring CB Insights’ Team of Agents to streamline their workflows and accelerate decision-making across research, diligence, briefings, and more – saving months of work.
"The Scouting Report Agent is amazing – it's a huge time saver and lets us respond quickly with enough insight to get back to a client or be dangerous with," said Bethany Boutin, Business & Market Intelligence Lead: Commercial Solutions + Digital at Evernorth Health Services, a subsidiary of The Cigna Group.
"Most AI agents today are generalists trying to do everything – but when it comes to strategic decisions, you need specialists who understand your business context and have access to reliable external intelligence," said Manlio Carrelli, CEO of CB Insights. "Our Team of Agents represents the evolution from generic AI assistants to purpose-built intelligence operatives. They work around the clock on your behalf, each one an expert in their domain, all powered by our double-verified Business Graph and data science on the world's companies and markets – insights and data that are not available on ChatGPT, the Internet, or in any other agent."
Addressing the External Intelligence Gap
While most enterprise strategic decisions require external market intelligence about competitors, markets, and potential partners, existing AI tools often lack the specialized context and validated data necessary for high-stakes business decisions. CB Insights' growing Team of Agents solves this, starting with 11 specialized agents that deliver:
- Acquisition Hunter: Identifies strategic acquisition targets and early-stage disruptors before competitors notice them
- Business Relationship Analyst: Maps customer, vendor, and partner relationships to reveal strategic insights
- ChatCBI: Serves as an AI-to-AI interface, allowing enterprises to integrate CB Insights intelligence directly into their existing AI workflows
- Commercial Due Diligence Accelerator: Reduces due diligence timelines from weeks to hours with automated expert interviews and risk assessments
- Competitive Sentinel: Monitors what competitors are buying, building, and investing in before it appears in financials
- Deep Analyst: Generates comprehensive research reports and market analyses in hours instead of weeks
- Earnings Analyst: Delivers CEO-ready competitive intelligence within hours of earnings calls
- Partner and New Business Finder: Detects high-value partnership and sales opportunities using funding and competitive signals
- Personal Briefing: Scours global news to surface personalized growth opportunities and competitive threats
- Sales Account Planner: Accelerates rep ramp-up with deep account understanding and tailored pitch strategies
- Scouting Report: Generates analyst-grade SWOT analyses on any private company on command
The agents listed are not exhaustive and CB Insights’ clients can create their own with Microsoft Copilot, MCP, and soon directly in ChatCBI.
Agents Powered by the World's Most Comprehensive Business Graph
Unlike AI agents that rely on public web data or limited datasets, CB Insights' Team of Agents operates on the proprietary Business Graph – a continuously validated dataset with patented data science covering management teams, funding rounds, partnerships, deals, earnings calls, hiring patterns, patents, and more across global business activity.
"The quality of AI output depends entirely on the quality of data input," said Carrelli. "Our agents don't just scrape the web – they work with double-verified intelligence based on proprietary information collected from companies and their customers directly, unique datasets like their commercial relationships, and proprietary data science that scores future potential. This means when our Competitive Sentinel tells you a rival is planning a major acquisition, or when our Acquisition Hunter identifies a strategic target, you can make decisions with confidence."
Designed for Enterprise Integration
The Team of Agents operates across multiple platforms where strategic work happens:
- Native integration with CB Insights' Strategy Terminal for comprehensive market intelligence workflows
- Microsoft 365 Copilot integration for seamless incorporation into existing productivity tools
- Model Context Protocol (MCP) compatibility for any MCP-compatible AI agent to tap into CB Insights' datasets and tools – including ChatCBI – without a single line of code
- API and custom solutions for embedding intelligence into enterprise applications and workflows
- CB Insights’ forward-deployed strategists work with you to automate your research and strategy flows with custom agents
"We're not asking enterprises to change how they work – we're making their existing workflows dramatically more intelligent," said Carrelli. "Whether you're in Excel building a market model, in PowerPoint preparing for a board meeting, or doing deep work inside the CB Insights terminal, our agents provide the external intelligence you need exactly when and where you need it."
Availability and Pricing
CB Insights' Team of Agents is available immediately to enterprise customers through flexible deployment options. Individual agents can be deployed for specific use cases, or enterprises can access the full team for comprehensive market intelligence automation.
For more information about CB Insights' Team of Agents and to request a demonstration, visit www.cbinsights.com/team-of-agents.
About CB Insights
Headquartered in New York City, CB Insights is the leading provider of AI for market intelligence. The company aggregates, validates, and analyzes hard-to-find private and public company data. Its powerful AI tells users what it all means to them personally. The world's smartest companies rely on CB Insights to focus on the right markets, stay ahead of competitors, and identify the right targets for sales, partnership, or acquisition. Visit www.cbinsights.com for more information.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250626444055/en/
Contacts
CB Insights
jason.saltzman@cbinsights.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom